-
Gregory CR, Stewart A, Sturges B, et al. Leflunomide effectively treats naturally occurring immune-mediated and inflammatory diseases of dogs that are unresponsive to conventional therapy. Transplant Proc. 1998;30(8):4143-4148.
-
Singer LM, Cohn LA, Reinero CR, Papich MG. Leflunomide pharmacokinetics after single oral administration to dogs. J Vet Pharmacol Ther. 2011;34(6):609-611.
-
Mehl ML, Tell L, Kyles AE, Chen YJ, Craigmill A, Gregory CR. Pharmacokinetics and pharmacodynamics of A77 1726 and leflunomide in domestic cats. J Vet Pharmacol Ther. 2012;35(2):139-146.
-
Bohanec Grabar P, Rozman B, Tomsic M, Suput D, Logar D, Dolzan V. Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients. Eur J Clin Pharmacol. 2008;64(9):871-876.
-
McChesney LP, Xiao F, Sankary HN, et al. An evaluation of leflunomide in the canine renal transplantation model. Transplantation. 1994;57(12):1717-1722.
-
Williams CR, Sykes JE, Mehl M, et al. In vitro effects of the active metabolite of leflunomide, A77 1726, on feline herpesvirus-1. Am J Vet Res. 2007;68(9):1010-1015.
-
Kyles AE, Gregory CR, Griffey SM, Bernsteen L, Jackson J, Morris RE. Leflunomide analog, MNA-715, plus cyclosporine reduces renal allograft rejection in mismatched dogs. Transplant Proc. 2001;33(1-2):368-369.
-
Kyles AE, Gregory CR, Griffey SM, et al. Immunosuppression with a combination of the leflunomide analog, FK778, and microemulsified cyclosporine for renal transplantation in mongrel dogs. Transplantation. 2003;75(8):1128-1133.
-
Lirtzman RA, Gregory CR, Levitski RE, et al. Combined immunosuppression with leflunomide and cyclosporine prevents MLR-mismatched renal allograft rejection in a mongrel canine model. Transplant Proc. 1996;28(2):945-947.
-
Colopy SA, Baker TA, Muir P. Efficacy of leflunomide for treatment of immune-mediated polyarthritis in dogs: 14 cases (2006-2008). JAVMA. 2010;236(3):312-318.
-
Bianco D, Hardy RM. Treatment of Evans’ syndrome with human intravenous immunoglobulin and leflunomide in a diabetic dog. JAAHA. 2009;45(3):147-150.
-
Affolter VK, Moore PF. Canine cutaneous and systemic histiocytosis: reactive histiocytosis of dermal dendritic cells. Am J Dermatopathol. 2000;22(1):40-48.
-
Hanna FY. Disease modifying treatment for feline rheumatoid arthritis. Vet Comp Orthop Traumatol. 2005;18(2):94-99.
-
Chan V, Charles BG, Tett SE. Rapid determination of the active leflunomide metabolite A77 1726 in human plasma by high-performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;803(2):331-335.
-
van Roon EN, Jansen TL, van de Laar MA, et al. Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentrations predict response to treatment in patients with rheumatoid arthritis. Ann Rheum Dis. 2005;64(4):569-574.
-
Gupta R, Bhatia J, Gupta SK. Risk of hepatotoxicity with add-on leflunomide in rheumatoid arthritis patients. Arzneimittelforschung. 2011;61(5):312-316.
-
van Roon EN, Jansen TL, Houtman NM, Spoelstra P, Brouwers JR. Leflunomide for the treatment of rheumatoid arthritis in clinical practice: incidence and severity of hepatotoxicity. Drug Saf. 2004;27(5):345-352.